"The Company also expects revenues to increase further as invoices are calculated during December 2017 and looks forward to updating the market as these figures become available.
This surge in revenue can be attributed to an expansion of the Company’s domestic distribution channels, recent additions to Bod’s evidence-based, natural medicines and skincare products, and the commencement of international sales via key Daigou relationships."
Expecting more lucrative deals to be announced as well....
"The Company is negotiating with a number of parties to increase sales into lucrative Asian markets and looks forward to updating shareholders on its progress in the near term."
And also expanding sales locally...
"The Company remains in ongoing discussions with a number of additional banner groups and aims to expand distribution channels further throughout 2018."
BDA Price at posting:
58.5¢ Sentiment: Buy Disclosure: Held
